Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

Shionogi Acquires Tetra Therapeutics

May 26, 2020

Biotechnology

Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.

Bain Capital-Led Consortium Acquires Hitachi Metals

October 26, 2022

Manufacturing

A consortium led by Bain Capital Private Equity, together with Japan Industrial Partners (JIP) and Japan Industrial Solutions (JIS), closed a tender offer to acquire Hitachi Metals, Ltd. The investors said they will provide capital and management support to accelerate growth and pursue opportunities in areas such as electric vehicles; Hitachi Metals reported ¥942.7 billion in revenue and about 27,700 employees as of March 2022.

KKR Acquires Bushu Pharmaceuticals from BPEA EQT

December 20, 2022

Pharmaceuticals

KKR has agreed to acquire Bushu Pharmaceuticals, a leading Japanese pharmaceutical CDMO headquartered in Kawagoe, from the BPEA V Fund (BPEA EQT). Bushu operates four manufacturing facilities across Japan, employs around 1,600 people, and provides contract development and manufacturing services for pharmaceuticals and medical devices; the deal is expected to close in Q1 2023 subject to customary approvals.

Bain Capital and Kohlberg Lead Strategic Investment in PCI Pharma Services

July 14, 2025

Healthcare Services

PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), received a strategic growth investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala and a continuing minority stake from Partners Group. The capital will be used to accelerate PCI's organic and inorganic growth, expand sterile fill-finish and specialized manufacturing capacity, and broaden its geographic footprint to support biopharma customers and U.S. pharmaceutical supply-chain resilience.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Bain Capital Private Equity Acquires Showa Aircraft Industry

May 11, 2020

Manufacturing

Bain Capital Private Equity completed a majority buyout of Showa Aircraft Industry Co., Ltd., paying approximately ¥90 billion (US$817 million) and delisting the company from the Tokyo Stock Exchange. Bain said it will support redevelopment of Showa Aircraft’s significant real estate assets in Akishima and leverage operational expertise to grow the company’s manufacturing business, which produces honeycomb core panels and other transportation-industry components.